S-1/A: OS Therapies Files Amendment for $15 Million Equity Line of Credit Resale

OS Therapies Incorporated has filed an amendment to its registration statement for the resale of up to $15 million in common stock through an equity line of credit with Square Gate Capital Master Fund, LLC.

Summary

• OS Therapies has filed an amendment to its Form S-1 registration statement related to a committed equity facility (ELOC) with Square Gate Capital Master Fund, LLC.
• The filing covers the resale of up to $15 million of common stock, plus 165,746 initial commitment shares and up to 450,000 true-up shares.
• The true-up shares will be issued if the stock price on the effective date of the registration statement is below $2.715.
• OS Therapies will not receive any proceeds from the resale of shares by the investor, but may receive up to $15 million in gross proceeds from the investor under the ELOC agreement.
• The company intends to use any proceeds from the facility to advance clinical development programs, expand research activities, and for general corporate purposes.
• The ELOC agreement will remain in effect until the earlier of October 31, 2026, or when the investor has purchased the maximum commitment amount.
• The investor is restricted from owning more than 4.99% of the company's outstanding shares.
• The company's lead product candidate is OST-HER2, an immunotherapy for Osteosarcoma, with topline results expected in the fourth quarter of 2024.
• OS Therapies also owns rights to the OST-tADC platform, a next-generation antibody-drug conjugate technology.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential for funding and the development of promising technologies, the company's financial situation and the risks associated with the ELOC agreement raise concerns. The going concern warning and lack of revenue generation are significant negatives.

Positives

• The equity line of credit provides a potential source of funding for the company's operations and development programs.
• The company has a lead product candidate, OST-HER2, in Phase IIb clinical trials with topline results expected soon.
• The company owns rights to the OST-tADC platform, a next-generation antibody-drug conjugate technology, which could provide future growth opportunities.
• The company has received orphan drug designation for OST-HER2 in the United States.

Negatives

• The sale of a substantial number of shares could adversely affect the market price of the company's stock.
• The company may use the proceeds from the ELOC in ways that may not yield a significant return.
• The company is a clinical stage biopharmaceutical company and has not generated any revenue to date from drug sales.
• The company has incurred significant operating losses and anticipates continued losses for the foreseeable future.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Risks

• The sale of a substantial number of shares under the ELOC could negatively impact the stock price.
• The company may not be able to predict the actual number of shares sold or the gross proceeds from the ELOC.
• Investors who buy shares at different times may pay different prices.
• The company may use the proceeds in ways that may not yield a significant return.
• The company has not generated any revenue from drug sales and may never become profitable.
• The company has incurred significant operating losses and anticipates continued losses.
• The company may be unable to raise capital when needed or on attractive terms.
• The company's ability to utilize net operating loss carryforwards may be limited.
• The company depends heavily on the success of OST-HER2 and OST-tADC.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may experience delays in patient enrollment for clinical trials.
• The company's product candidates may cause adverse side effects.
• The company may not be able to obtain or maintain orphan drug designation or exclusivity.
• The company may be subject to ongoing obligations and continued regulatory review.
• The company may encounter difficulties in manufacturing its product candidates.
• The company's future growth may depend on its ability to penetrate foreign markets.
• The company may not be able to obtain and maintain patent and other intellectual property protection.
• The company may initiate or become a defendant in lawsuits to protect or enforce its intellectual property rights.
• The company may not obtain or grant licenses or sublicenses to intellectual property rights on favorable terms.
• The company may fail to comply with obligations in agreements under which it licenses intellectual property rights.
• The company's future success depends on its ability to retain key scientific employees and to attract, retain and motivate qualified personnel.
• The company's internal computer systems may fail or suffer security breaches.
• The company will incur increased costs as a result of operating as a public company.

Future Outlook

The company intends to use any proceeds from the facility to advance clinical development programs, expand research activities, and for general corporate purposes. The company expects topline results from the OST-HER2 clinical trial in the fourth quarter of 2024 and intends to seek regulatory approval for OST-HER2 for the prevention of metastases in Osteosarcoma in 2025.

Management Comments

• The company's mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
• The company is seeking to answer the call for new treatments that will prevent metastasis and the recurrence of metastases with its lead core product candidate OST-HER2.
• The company intends to evaluate OST-HER2's potential use in other solid tumors including breast, esophageal and lung cancers.
• The company intends to investigate clinical indications for OST-tADC in Osteosarcoma and other solid tumors.

Industry Context

The announcement reflects a common strategy for clinical-stage biopharmaceutical companies to secure funding for ongoing research and development. The focus on Osteosarcoma, a rare cancer, highlights the company's commitment to addressing unmet medical needs. The development of antibody-drug conjugate technology aligns with current industry trends in cancer therapeutics.

Comparison to Industry Standards

• The use of an equity line of credit is a common financing method for clinical-stage biotech companies, allowing access to capital as needed.
• The development of OST-HER2, an immunotherapy targeting HER2, is similar to other companies developing targeted therapies for cancer.
• The OST-tADC platform is a next-generation antibody-drug conjugate technology, which is a growing area of interest in the pharmaceutical industry.
• The company's focus on rare cancers is similar to other companies developing orphan drugs, which often receive regulatory incentives.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biotech industry.

Legal Proceedings

• On April 12, 2024, Noble Capital Markets, Inc. (Noble) filed a Demand for Arbitration against us in JAMS, claiming that we breached the anti-dilution provision in the parties advisory agreement by not issuing to Noble an additional 474,134 shares of our common stock.
• In September 2024, we settled the matter with Noble in exchange for $50,000 and 320,033 shares of our common stock, which were issued during September 2024.

Related Party Transactions

• The company issued convertible notes to Mill River Partners LLC, of which John Ciccio and Theodore F. Search, Pharm.D., members of the board of directors, are members of the board of managers.
• The company issued a convertible note to BlinkBio, Inc., of which Colin Goddard, Ph.D., the company's former Chairman, is the Chairman and Chief Executive Officer.
• The company had a shareholder loan with Paul A. Romness, MPH, the company's Founder, President, Chief Executive Officer and a member of the Board, which was paid off as of December 31, 2023.
• The company had a payroll payable to the CEO and related payroll taxes payable.
• The company has a bill in accounts payable to Shore Accountants MD Inc., an outside accounting firm that handles payroll and bookkeeping and is 100% owned by Christopher Acevedo, the CFO.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares under the ELOC agreement.
• Shareholders may experience a decline in the value of their shares due to the sale of a substantial number of shares.
• Employees may be affected by the company's financial performance and ability to continue operations.
• Customers may benefit from the development of new treatments for Osteosarcoma and other solid tumors.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company expects topline results from the OST-HER2 clinical trial in the fourth quarter of 2024.
• The company intends to seek regulatory approval for OST-HER2 for the prevention of metastases in Osteosarcoma in 2025.
• The company will continue preclinical and toxicology trials with the lead drug candidate for OST-tADC.
• The company will file for an investigational new drug application (IND) to initiate a Phase I trial in ovarian cancer and other folate receptor alpha overexpressing cancers.

Key Dates

Keywords

Equity Line of Credit, Osteosarcoma, Immunotherapy, Antibody-Drug Conjugate, OST-HER2, OST-tADC, Clinical Trials, Biopharmaceutical, Drug Development, Regulatory Approval